Related Experiment Video
Updated: Apr 18, 2026
08:56
Transient Expression in Nicotiana Benthamiana Leaves for Triterpene Production at a Preparative Scale
Published on: August 16, 2018
18.4K
Icetexane diterpenoids from Perovskia atriplicifolia
Zhi-Yong Jiang1, Yi-Jiang Yu1, Chao-Guan Huang1
1School of Chemistry and Biotechnology, Yunnan Minzu University, Kunming, Yunnan, China.
Planta Medica
|January 23, 2015
Summary
New compounds from Perovskia atriplicifolia show promising anti-hepatitis B virus activity. Compounds 1 and 2 effectively suppressed hepatitis B virus DNA replication in vitro.
Area of Science:
- Natural Product Chemistry
- Virology
- Medicinal Chemistry
Background:
- Perovskia atriplicifolia is a plant source of bioactive compounds.
- Hepatitis B virus (HBV) infection remains a significant global health concern.
- Natural products are explored for novel antiviral therapies.
Purpose of the Study:
- To isolate and characterize new icetexane diterpenoids from Perovskia atriplicifolia.
- To evaluate the anti-hepatitis B virus activity of isolated compounds.
- To identify potential novel therapeutic agents against HBV.
Main Methods:
- Isolation and purification of compounds using chromatographic techniques.
- Structure elucidation of new compounds via Mass Spectrometry (MS), Infrared (IR), and Nuclear Magnetic Resonance (NMR) spectroscopy (1D and 2D).
- In vitro anti-HBV activity assay using the HepG 2.2.15 cell line.
Main Results:
- Five new icetexane diterpenoids (perovskatones B-D, 1α-hydroxybrussonol, 1α-hydroxypisiferanol) and a new natural product were isolated.
- Compounds 1 and 2 demonstrated significant in vitro anti-HBV activity.
- Compounds 1 and 2 suppressed HBV DNA replication with high selectivity index values (154.3 and 137.7, respectively).
Conclusions:
- Perovskia atriplicifolia yields novel icetexane diterpenoids with anti-HBV potential.
- Compounds 1 and 2 are promising candidates for further development as anti-hepatitis B virus agents.
- The study highlights the therapeutic potential of natural products in combating viral infections.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
580
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
580
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
623
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
623